Tofacitinib
Active ingredient: Tofacitinib Citrate
In short: Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use Use of tofacitinib tablets in combination with biologic disease-modif
What is Tofacitinib used for?
Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.
Limitations of Use
Use of tofacitinib tablets in combination with biologic disease-modifying antirheumatic drugs (DMARDs) or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Tofacitinib tablets are indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers.
Limitations of Use
Use of tofacitinib tablets in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Tofacitinib tablets are indicated for the treatment of adult patients with active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.
Limitations of Use
Use of tofacitinib tablets in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
Tofacitinib tablets are indicated for the treatment of pediatric patients 2 years of age and older with of active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers. …
âš Boxed warning (FDA's strongest warning)
SERIOUS INFECTIONS
Patients treated with tofacitinib tablets are at increased risk for developing serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), that may lead to hospitalization or death . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Reported infections included:
• Active TB, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent TB before tofacitinib tablet use and during therapy. Treatment for latent infection should be initiated prior to tofacitinib tablet use. • Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.
The risks and benefits of tofacitinib tablets treatment should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after tofacitinib tablets treatment, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. If a serious infection develops, interrupt tofacitinib tablets until the infection is controlled . …
Tofacitinib dosage
Prior to initiating tofacitinib tablets, consider performing the following:
• Active and latent tuberculosis (TB) infection evaluation: If the patient has latent TB, treat for TB prior to tofacitinib tablets treatment .
• Viral hepatitis screening in accordance with clinical guidelines .
• A complete blood count: Avoid initiation of tofacitinib tablets treatment in patients with a lymphocyte count less than 500 cells/mm3, absolute neutrophil count less than 1000 cells/mm3, or hemoglobin level less than 9 g/dL .
• Baseline hepatic function evaluation: Tofacitinib tablets are not recommended for patients with severe hepatic impairment .
• Update immunizations according to current immunization guidelines. The interval between live vaccinations and initiation of tofacitinib tablets should be in accordance with current vaccination guidelines regarding immunosuppressive agents .
• XELJANZ XR (extended-release tablets) is not substitutable with tofacitinib tablets. Switching between tofacitinib tablets and XELJANZ XR should be made by the healthcare provider. • Dose interruption is recommended for management of lymphopenia, neutropenia, and anemia .
• Interrupt use of tofacitinib tablets if a patient develops a serious infection until the infection is controlled .
• Take tofacitinib tablets with or without food .
Table 1 displays the recommended dosage of tofacitinib tablets for adults with RA, PsA, and AS with and without renal impairment (including those who are undergoing hemodialysis) or hepatic impairment . The table also displays the recommended dosage modifications for patients concomitantly using CYP2C19 and/or CYP3A4 inhibitors , and patients with lymphopenia, neutropenia, or anemia.
Table 1: Recommended Dosage of Tofacitinib Tablets in Adults with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Adults | Tofacitinib Tablet
Patients with Normal Renal and Hepatic Functiona | 5 mg twice daily
Recommended Dosage in Patients with Renal Impairment (RI)b
Mild RI (CLcr >50 and ≤80 mL/min) | 5 mg twice daily
Moderate RI (CLcr ≥30 and ≤50 mL/min) | 5 mg once daily
Severe RI (CLcr <30 mL/min) | 5 mg once daily
For patients undergoing hemodialysis, administer the dose after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended after dialysis.
Recommended Dosage in Patients with Hepatic Impairment (HI)
Mild HI (Child-Pugh A) | 5 mg twice daily
Moderate HI (Child-Pugh B) | 5 mg once daily
Severe HI (Child-Pugh C) | Use of tofacitnib tablets is not recommended. …
How to take Tofacitinib — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Medication Guide).
Serious Infections
Inform patients that tofacitinib tablets may lower the ability of their immune system to fight infections. Advise patients not to start taking tofacitinib tablets if they have an active infection. Instruct patients to contact their healthcare provider immediately during treatment if symptoms suggesting infection appear to ensure rapid evaluation and appropriate treatment.Instruct patients to contact their healthcare provider immediately during treatment if they, their partner, or caregiver notice new onset or worsening of neurological symptoms including general muscle weakness, disturbance of vision, changes in thinking, memory and orientation leading to confusion and personality changes as these may be symptoms of a very rare, serious brain infection called progressive multifocal leukoencephalopathy (PML).
Advise patients that the risk of herpes zoster, some cases of which can be serious, is increased in patients treated with tofacitinib tablets . …
Warnings & precautions
Do not take this medicine if: None.
Serious and sometimes fatal infections may occur with tofacitinib tablets. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib tablets. The most common serious infections reported with tofacitinib tablets included pneumonia, urinary tract infection, cellulitis, herpes zoster, bronchitis, septic shock, diverticulitis, gastroenteritis, appendicitis, and sepsis. Among opportunistic infections, tuberculosis and other mycobacterial infections, cryptococcosis, histoplasmosis, esophageal candidiasis, pneumocystosis, multi-dermatomal herpes zoster, cytomegalovirus infections, BK virus infection, and listeriosis were reported with tofacitinib tablets. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunomodulating agents such as methotrexate or corticosteroids.In the UC population, treatment with tofacitinib tablets 10 mg twice daily was associated with greater risk of serious infections compared to 5 mg twice daily. Additionally, opportunistic herpes zoster infections (including meningoencephalitis, ophthalmologic, and disseminated cutaneous) were seen in patients who were treated with tofacitinib tablets 10 mg twice daily.
Other serious infections that were not reported in clinical studies may also occur (e.g., coccidioidomycosis).
Avoid use of tofacitinib tablets in patients with an active, serious infection, including localized infections. …
Tofacitinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
• Serious Infections
• Increased Risk of Mortality
• Malignancy and Lymphoproliferative Disorders
• Major Adverse Cardiovascular Events
• Thrombosis
• Gastrointestinal Perforations
• Hypersensitivity Reactions
• Hypoglycemia in Patients with Diabetes
• Laboratory Abnormalities
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.
The clinical studies described in this subsection were conducted using tofacitinib tablets and/or XELJANZ oral solution.
Adverse Reactions in Adults with Rheumatoid Arthritis
In RA Safety Study 1, 1,455 adults were treated with tofacitinib tablets 5 mg twice daily, 1,456 adults were treated with 10 mg twice daily, and 1,451 adults were treated with a TNF blocker for a median of 4 years . A dosage of tofacitinib tablets 10 mg twice daily is not recommended for the treatment of RA because of increased risks . For the treatment of adults with moderately to severely active RA , the recommended dosage of tofacitinib tablets is 5 mg twice daily.
The safety of tofacitinib tablets was also evaluated in two Phase 2 and five Phase 3 double-blind, placebo-controlled, multicenter trials in patients with RA. …
Drug interactions
Table 7 includes drugs with clinically significant drug interactions when concomitantly used with tofacitinib tablets and instructions for preventing or managing them.
Table 7: Clinically Significant Interactions Affecting Tofacitinib Tablets When Concomitantly Used with Other Drugs
Strong CYP3A4 Inhibitors (e.g., ketoconazole)
Clinical Impact | Increased exposure to tofacitinib
Intervention | Dosage modification of tofacitinib tablets is recommended
Moderate CYP3A4 Inhibitors Concomitantly Used with Strong CYP2C19 Inhibitors (e.g., fluconazole)
Clinical Impact | Increased exposure to tofacitinib
Intervention | Dosage modification of tofacitinib tablets is recommended
Strong CYP3A4 Inducers (e.g., rifampin)
Clinical Impact | Decreased exposure to tofacitinib and may result in loss of or reduced clinical response
Intervention | Concomitant use with tofacitinib tablets is not recommended
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)
Clinical Impact | Risk of added immunosuppression; concomitant use of tofacitinib tablets with biologic DMARDs or potent immunosuppressants has not been studied in patients with RA, PsA, AS, UC, or pcJIA.
Intervention | Concomitant use with tofacitinib tablets is not recommended
About this medicine
Tofacitinib tablets are formulated with the citrate salt of tofacitinib, a JAK inhibitor.
Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1).
The solubility of tofacitinib citrate in water is 2.9 mg/mL.
Tofacitinib citrate has a molecular weight of 504.5 Daltons (or 312.4 Daltons as the tofacitinib free base) and a molecular formula of C16H20N6O•C6H8O7. The chemical structure of tofacitinib citrate is:
Tofacitinib tablets are supplied for oral administration as a 5 mg white to off white, round shaped, film coated tablets. Each tablet of tofacitinib contains 5 mg of tofacitinib (equivalent to 8.08 mg of tofacitinib citrate) and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6 mPas, titanium dioxide, macrogol/PEG MW 3350, triacetin. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 10403307-e2f9-44d1-bc72-552fdba299d1. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine